Wegovy is a once-weekly prescription injection used for chronic weight management in adults and certain adolescents with obesity or overweight conditions. It contains semaglutide, a GLP-1 receptor agonist that helps regulate appetite and calorie intake. Wegovy is manufactured by Novo Nordisk and is specifically approved for weight loss, unlike its related diabetes medication counterpart, Ozempic.
What Is Wegovy Used For?
Wegovy is FDA-approved for:
-
Adults with obesity (BMI ≥30)
-
Adults who are overweight (BMI ≥27) with at least one weight-related condition (e.g., hypertension, type 2 diabetes, or high cholesterol)
-
Adolescents (12+) with obesity (in certain cases)
It is prescribed alongside a reduced-calorie diet and increased physical activity to support sustainable, long-term weight management.
How Wegovy Works
Wegovy mimics the GLP-1 (glucagon-like peptide-1) hormone that targets areas of the brain involved in appetite regulation. It works by:
-
Reducing hunger signals
-
Increasing feelings of fullness
-
Slowing gastric emptying
-
Supporting better blood sugar control
These effects help decrease overall calorie intake, making weight loss more achievable when combined with lifestyle changes.
Clinical Results
Clinical trials have shown that individuals using Wegovy, along with diet and exercise, achieved significant weight loss compared to placebo. Many patients experienced substantial reductions in body weight over a 68-week period.
Results vary based on adherence, dosage, and individual metabolic factors.
Dosage & Administration
Wegovy is administered as a once-weekly subcutaneous injection. Treatment begins at a lower dose and gradually increases over several weeks to minimize gastrointestinal side effects.
Possible Side Effects
Common side effects may include:
-
Nausea
-
Vomiting
-
Diarrhea
-
Constipation
-
Abdominal pain
These symptoms are typically mild to moderate and decrease over time.
Serious but rare risks may include pancreatitis, gallbladder disease, and potential thyroid C-cell tumors (observed in animal studies).
Who Should Avoid Wegovy?
Wegovy should not be used in individuals with:
-
Personal or family history of medullary thyroid carcinoma
-
Multiple endocrine neoplasia syndrome type 2 (MEN 2)
-
Severe allergic reactions to semaglutide
Always consult a licensed healthcare provider before starting Wegovy to determine if it is safe and appropriate for your health condition.
Final Thoughts
Wegovy is a clinically proven weight-loss medication that supports appetite control and long-term metabolic health. When combined with lifestyle modifications, it offers an effective medical option for individuals struggling with obesity or excess weight.
